- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2013
- Public Summary Document (PSD) March 2013 PBAC Meeting - PDF
Dabrafenib – March 2013
Dabrafenib, capsule, 50 mg and 75 mg, Tafinlar®
Last updated
8 November 2023